# PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2014

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-Q
- Filed: 2014-09-15
- Accepted by EDGAR: Sep 15, 2014, 08:24 ET
- Period: 2014-07-31
- Accession: 0001019687-14-003582
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000101968714003582/nuvilex_10q-073114.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000101968714003582/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-07-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-05-01 to 2014-07-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months, 2014-05-01 to 2014-07-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2014-05-01 to 2014-07-31 | $0 | us-gaap:GrossProfit |
| Operating income | 3 months, 2014-05-01 to 2014-07-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-05-01 to 2014-07-31 | $2.7k | us-gaap:InterestExpense |
| Net income | 3 months, 2014-05-01 to 2014-07-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2014-05-01 to 2014-07-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2014-05-01 to 2014-07-31 | −$786.8k | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2014-07-31 | $2.9m | us-gaap:Cash |
| Current assets | at 2014-07-31 | $3.1m | us-gaap:AssetsCurrent |
| Total assets | at 2014-07-31 | $8.2m | us-gaap:Assets |
| Current liabilities | at 2014-07-31 | $371.4k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-07-31 | $371.4k | us-gaap:Liabilities |
| Shareholders' equity | at 2014-07-31 | $7.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 5,944 characters.

*This following information specifies certain forward-looking statements of our management. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may”, “shall”, “could”, “expect”, “estimate”, “anticipate”, “predict”, “probable”, “possible”, “should”, “continue”, or similar terms, variations of those terms or the negative of those terms. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict, and no representation, guaranty, or warranty is to be inferred from those forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements.*

#### Forward-looking statements include, but are not limited to, the following:

- *Statements relating to our future business and financial performance;*
- *Statements relating to future preclinical studies, clinical trials and regulatory approvals of our products;*
- *Statements relating to our competitive position; and*
- *Other material future developments that you may take into consideration.*

### Results of Operations for the Three Months Ended July 31, 2014 and 2013

The Company, through its acquisition of Bio Blue Bird AG (“Bio Blue Bird”), successfully completed its first acquisition as a biotechnology company. Bio Blue Bird is now a wholly-owned subsidiary of the Company that holds the exclusive worldwide licensing rights to the use of the Cell-in-a-Box® live cell encapsulation technology for treating pancreatic cancer.

The Company is now actively engaged with Austrianova Singapore and other entities in preparation for a new Phase 2b clinical trial for the treatment of pancreatic cancer using encapsulated live cells that are the same as those employed in the previous Phase 1/2 clinical trial. We are currently working together to advance clinical research and development of new cellular-based therapies in the oncology arena. Due to this significant successful acquisition, the Company business is that of a biotechnology company with a specialty in the use of the Cell-in-a-Box® live cell encapsulation technology in developing treatments for serious and deadly diseases. The Company’s focus for the present and immediate future is in the oncology and diabetes arenas.

### Selling, General and Administrative Expenses

For the three months ended July 31, 2014, sales and marketing expense increased by $215,500 from $15,000 for the same period in the prior year. The increase is a result of the company’s efforts to promote its new focus on becoming a world-class biotechnology company.

For the three months ended July 31, 2014, compensation expense decreased by $948,709 to $253,418, as compared to $1,202,127 for the same period in the prior year. The decrease is a result of fewer shares of common stock being issued for compensation during the period.

For the three months ended July 31, 2014, legal and professional fees increased by $196,506 to $260,864 from $64,358 for the same period in the prior year. The increase is attributed to an increase in attorney fees for work being done for the Company.

General and administrative expenses during the three months ended July 31, 2014 compared to the three months ended July 31, 2013, increased by $719,172 to $838,378 as compared to $119,206 in the prior period. The increase can be attributed to increased travel expense, investor relations and other consulting service expense. This expense also includes the $297,500 non-cash expense from the issuance of the common stock to Lincoln Park in accordance with the provisions of the termination agreement.

During the three months ended July 31, 2014, net loss decreased by $3,081,543 to $1,584,824, as compared to $4,666,367 in the prior period. The decrease in net loss can mainly be attributed to the absence of the loss on conversion of preferred stock and conversion of debt that existed in the prior period.

### Liquidity and Capital Resources

For the three months ended July 31, 2014, the Company used cash of $786,814 in operations and obtained cash of $67,283 from financing activities.

On May 28, 2014, the Company entered into a financial advisory, offering and at the market offering engagement agreement (“Chardan Agreement”), with Chardan Capital Markets, LLC (“Chardan”) pursuant to which Chardan agreed to use its reasonable best efforts to act as the Company’s sales agent in connection with the sale of common stock in “at the market” or privately negotiated transactions of up to $50 million, depending upon market conditions and at the sole discretion of the Company. In connection with such transactions, the Company agreed to pay Chardan: (i) a cash fee of 3% of the gross proceeds from the sale of any shares of common stock sold in an “at-the-market” offering and (ii) a cash fee of 7% of the aggregate sales price of any distinct blocks of common stock sold under the Chardan Agreement, plus five-year warrants representing 5% of the number of shares of common stock sold. In addition, the Company’s has agreed to reimburse certain expenses of Chardan in an amount not to exceed $15,000.

## Controls and procedures

As filed, 2,588 characters.

The Company's management, including the Chief Executive Officer, President and General Counsel of the Company, as its principal executive officer, and the Chief Financial Officer of the Company, as its principal financial officer (collectively, “Principal Executive Officers”), have evaluated the effectiveness of the Company's “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based upon this evaluation, the Principal Executive Officers have concluded that, as of July 31, 2014, the Company's disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits to the SEC pursuant to the Exchange Act is recorded, processed, summarized and reported within the time period specified by the SEC’s rules and forms and is accumulated and communicated to the Company's management, including its Principal Executive Officer, as appropriate to allow timely decisions regarding required disclosures.

Although the management of our Company, including the Principal Executive Officers, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

## Risk factors

As filed, 538 characters.

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2014. The information set forth in these Reports could materially affect the Company’s business, financial position and results of operations. There are no material changes from the risk factors set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Forms 10-K for the fiscal year ended April 30, 2014.

Filed Sep 15, 2014.
Source: SEC EDGAR, the filing index for accession 0001019687-14-003582. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
